Biopharma Muscle Disorder Therapies sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma Muscle Disorder Therapies
1.1 - About Biopharma Muscle Disorder Therapies sector
Companies in the Biopharma Muscle Disorder Therapies category discover, develop, and commercialize pharmacologic treatments for muscle diseases, spanning rare neuromuscular conditions and high-burden spasticity and sarcopenia. They deliver disease-modifying and symptomatic relief through small molecules, biologics, gene and oligonucleotide platforms, supported by specialized clinical, regulatory, and market access capabilities to reach specialty clinics, hospital systems, and payers.
Offerings typically include exon‑skipping antisense oligonucleotides for dystrophin restoration, AAV‑based microdystrophin gene therapies, complement pathway monoclonal antibodies and FcRn antagonists for autoimmune neuromuscular disorders, and myostatin inhibitors targeting sarcopenia. Many also advance enzyme replacement therapies for metabolic myopathies, botulinum toxin for focal spasticity, and oral antispasmodics. Companies pair these assets with GMP biologics and vector manufacturing, clinical trial operations, pharmacovigilance, and specialty distribution capabilities.
They serve neuromuscular clinics and hospital systems, rare disease patient populations, and payers and health plans. Outcomes include improved functional strength and mobility, reduced disease progression and spasticity episodes, shorter hospital stays, and lower total cost of care through orphan‑drug access and adherence programs. They also enable expanded treatment options across indications such as DMD, myasthenia gravis, and metabolic myopathies.
2. Buyers in the Biopharma Muscle Disorder Therapies sector
2.1 Top strategic acquirers of Biopharma Muscle Disorder Therapies companies
Avidity Biosciences
- Description: Provider of RNA therapeutics leveraging proprietary Antibody Oligonucleotide Conjugate (AOC) technology that fuses monoclonal antibodies with oligonucleotide therapies to enable targeted delivery for rare muscle diseases and genetic cardiomyopathies.
- Key Products:
- AOC Platform: Proprietary Antibody Oligonucleotide Conjugate technology combining monoclonal antibodies with oligonucleotides to deliver RNA precisely to targeted tissues previously unreachable with existing therapies
- Myotonic Dystrophy Type 1 (DM1) Clinical Program: AOC-based therapy delivering RNA into muscle to modify DM1 pathology and improve outcomes in this rare muscle disease
- Duchenne Muscular Dystrophy (DMD) Clinical Program: Investigational AOC therapeutic aimed at restoring dystrophin expression and slowing disease progression in people with DMD
- Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Program: AOC candidate designed for targeted RNA delivery to skeletal muscle to address the genetic cause of FSHD and preserve muscle function.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma Muscle Disorder Therapies sector
M&A buyer group 1: Neurology
Lundbeck
- Type: N/A
- Employees: ●●●●●
- Description: Provider of pharmaceutical contract development and manufacturing services specializing in solid-dosage drug products, offering end-to-end development, clinical and commercial batch production, analytical, packaging and supply-chain support from ISO-certified sites in Denmark and France.
- Key Products:
- Contract Development & Manufacturing (CDM): Provides formulation development, clinical and commercial solid-dosage production plus integrated packaging using advanced facilities in Denmark and France, enabling rapid time-to-market
- Analytical Services: Operates fully equipped laboratories delivering comprehensive testing and regulatory-compliant analytical support throughout product lifecycle to ensure quality and safety
- Supply Chain Services: Manages storage and global shipping, including controlled narcotic and psychotropic products, ensuring continuous availability and full regulatory compliance for customers
- Quality & HSE Management: Implements ISO 14001 and ISO 45001 certified quality, safety and environmental systems that safeguard high manufacturing standards and operational excellence across all activities.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma Muscle Disorder Therapies sector
3.1 - Buyout funds in the Biopharma Muscle Disorder Therapies sector
2.2 - Strategic buyer groups for Biopharma Muscle Disorder Therapies sector
4 - Top valuation comps for Biopharma Muscle Disorder Therapies companies
4.2 - Public trading comparable groups for Biopharma Muscle Disorder Therapies sector
Valuation benchmark group 1: Rare Disease Drug Developers
Novartis
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and treatments, focusing on the research, development, manufacturing, and marketing of patented pharmaceuticals in areas such as oncology, immunology, cardiovascular, ophthalmology, and neuroscience to improve and extend lives worldwide.
- Key Products:
- Oncology Treatments: Medications for various types of cancer
- Immunology Drugs: Treatments for autoimmune and inflammatory diseases
- Cardiovascular Medicines: Drugs for heart and vascular conditions
- Neuroscience Therapies: Pharmaceuticals for neurological and psychiatric disorders
- Ophthalmology Solutions: Treatments for eye diseases and conditions